Harvard Bioscience (HBIO) Capital Expenditures (2010 - 2026)
Harvard Bioscience (HBIO) reported Capital Expenditures of $426000.0 for Q1 2026, down 16.96% year-over-year from $513000.0 in Q1 2025, and down 5.12% quarter-over-quarter from $449000.0 in Q4 2025.
Harvard Bioscience (HBIO) Capital Expenditures (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has 17 years of Capital Expenditures data on file, last reported at $426000.0 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $426000.0, down 16.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 53.38% YoY), and the FY2025 annual result was $1.3 million, down 52.42% from the prior year.
- Capital Expenditures declined to $426000.0 in Q1 2026 per HBIO's latest filing, from $449000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $880000.0 in Q3 2024 and troughed at $89000.0 in Q2 2025.
- A 5-year average of $453294.1 and a median of $442000.0 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures surged 305.53% in 2024, then plunged 89.12% in 2025.
- A 5-year view of Capital Expenditures shows it stood at $235000.0 in 2022, then surged by 253.19% to $830000.0 in 2023, then plunged by 63.73% to $301000.0 in 2024, then soared by 49.17% to $449000.0 in 2025, then fell by 5.12% to $426000.0 in 2026.
- Business Quant data shows HBIO's Capital Expenditures at $426000.0 in Q1 2026, $449000.0 in Q4 2025, and $207000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 103.30 Mn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 125.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 96.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 33.65 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 26.10 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 84.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 86.40 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 30.79 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 137.00 Mn |
| 10 | Harvard Bioscience | 26.17 Mn | 19.07 Mn | 12.24 Mn | 426,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 426,000.00 |
| Mar 31, 2026 | 426,000.00 |
| Dec 31, 2025 | 449,000.00 |
| Dec 31, 2025 | 449,000.00 |
| Sep 30, 2025 | 207,000.00 |
| Sep 30, 2025 | 207,000.00 |
| Jun 30, 2025 | 89,000.00 |
| Jun 30, 2025 | 89,000.00 |
| Mar 31, 2025 | 513,000.00 |
| Mar 31, 2025 | 513,000.00 |
| Dec 31, 2024 | 301,000.00 |
| Dec 31, 2024 | 301,000.00 |
| Sep 30, 2024 | 880,000.00 |
| Sep 30, 2024 | 880,000.00 |
| Jun 30, 2024 | 818,000.00 |
| Jun 30, 2024 | 818,000.00 |
| Mar 31, 2024 | 645,000.00 |
| Mar 31, 2024 | 645,000.00 |
| Dec 31, 2023 | 830,000.00 |
| Dec 31, 2023 | 830,000.00 |